Paul Peter Tak sold $157k of CADL
Chief Executive Officer at Candel Therapeutics, Inc.. 21,704 shares at an average of $7.23, traded Jan 15, 2025, filed Jan 17, 2025.
Score components
- +25RoleCEO
- +11Trade size$157k at market
- 0Share of holdings soldSold 7.9% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-006724, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | SOpen-market sale Common Stock | -21,704 | $7.23 | $157k | 251,912 | Jan 17, 2025 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 35Weak | sell10b5-1 | CADL Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $3.2M | 280,245 | |
| 14Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $282k | 32,146 | |
| 38Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $230k | 26,172 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $397k | 45,316 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Charles Schoch See Remarks | $44k | 5,000 | |
| 19Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $276k | 31,278 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $98k | 13,534 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $75k | 10,428 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Charles Schoch See Remarks | $69k | 9,511 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $103k | 14,322 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.